This site is intended for health professionals only

FDA approves two Mylan treatments


Pharmaceutical company Mylan has received Food and Drug Administration (FDA) approval for a depression and high blood pressure treatment.

The FDA gave the green light to Losartan, a generic version of Merck’s anti-hypertensive drug Hyzaar, which the company has already started to ship.

Bupropion hydrochloride, a copy of GSK’s antidepressant drug Wellbutrin SR, was also passed by regulators, Mylan said.

The firm currently has 141 new drugs awaiting FDA approval, representing about £63 billion in annual sales.

Thirty-eight of these are potential first-to-file opportunities.

Mylan, which was formed in 1961, specialises in generic pharmaceuticals. It is the third largest company of its kind in the world and makes more than 45 billion doses every year.

Copyright Press Association 2010

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine